The effects of 24 weeks losartan and ramipril treatment, both alone and in combination, on left ventricular mass (LVM), circulating transforming growth factor b1 (TGFb1), procollagen type I (PIP) and III (PIIIP), have been evaluated in hypertensive (HT) patients. A total of 57 HT with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized doubleblind, three arms, double dummy, independent trial was used. All HT patients were randomly allocated to three treatment arms consisting of losartan (50 mg/daily), ramipril (5 mg/ daily) and combined (losartan 50 mg/ daily þ ramipril 5 mg/daily) for 24 weeks. TGFb1, PIP and PIIIP, LVM, LVM/h 2.7 and other echocardiographic measurements, blood urea nitrogen, creatinine and clearance and potassium were determined after run in and after 24 weeks. All groups were comparable for gender, age, body mass index, blood pressure and LVM. The prevalence of baseline left ventricular hypertrophy (LVH) was not significantly different among three groups. At the end of treatment, a significant (Po0.05) reduction in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP), TGFb1, PIP, PIIIP, LVM and LVM/h 2.7 was observed in all groups. The absolute and percent reduction in TGFb1 and LVM/h 2.7 were significantly higher in combined than losartan or ramipril groups and also in HT patients with LVH. No significant change in absolute and percent reduction of SBP, DBP and MBP were found. Our data indicate an additional cardioprotective effect of dual blockade of renin-angiotensin in HT patients.
Introduction
Reduction in left ventricular mass (LVM) and regression of left ventricular hypertrophy (LVH) is one of the most important goal of antihypertensive therapy.
1,2 Disproportional accumulation of fibrous tissue is a major characteristic of the adverse structural remodelling of cardiac tissue in hypertensive (HT) patients. The increased collagen type I and III synthesis by fibroblasts and unchanged or insufficient degradation by collagenase has been reported to promote systolic and diastolic dysfunction. [3] [4] [5] Haemodynamic and non-haemodynamic factors play a main role in the collagen turnover in hypertension. 6, 7 In view of this, transforming growth factor b1 (TGFb1) may be considered as a primary mediator of cardiovascular effects of angiotensin II. TGFb1 is a multifunctional cytokine that induces fibrosis in many tissues including kidney, blood vessels, lung and heart. 8 In the heart, three isoforms of TGFb1 are present although the level of the type 1 isoform is found to be particularly related to the development of LVH. In particular, experimental and clinical studies have demonstrated a direct relationship between TGFb1 overproduction, LVM and impaired left ventricular filling. 9, 10 In addition, the blocking of TGFb1 with monoclonal antibodies has been reported to be effective to neutralise myocardial fibrosis. 11 Even if antihypertensive drugs reverse LVH by lowering blood pressure (BP), meta-analyses of clinical trials have demonstrated that angiotensin-converting enzyme (ACE)-inhibitors (ACEi) and angiotensin II receptor blockers (ARB) decrease LVM more effectively than other antihypertensive drugs. 12 Despite recent results from the Valsartan in acute myocardial infarction trial study 13 did not report a beneficial of ACEi and ARB combination in heart failure, other recent studies have indicated that the combination of ACEi and ARB that inhibits two consecutive reninangiotensin-system (RAS) steps promotes a decrease in myocardial fibrosis and LVH. 14, 15 This effect is due to a diminished AT1 receptor activation by a decreased angiotensin II production. Other data indicate that administration of ACEi reduces the collagen content with consequent improvement of diastolic filling. Clinical data, comparing ACEi and ARB therapy in hypertensive heart disease, indicate that ARB have equivalent effects to ACEi on BP and LVH, and these actions seem partially independent by their haemodynamic effects. In these cases, reduction in the TGFb1 levels have been reported to improve myocardial fibrosis and diastolic dysfunction angiotensin II blockade mediated. 16 In addition, experimental studies indicate that the combination of low doses of ACEi and ARB have a synergic and most effectiveness on LVH. 15 These effects might explain a better cardioprotection attributed to ACEi and ARB than other antihypertensive drugs. Although a combination of ACEi and ARB treatment seems attractive, thus far limited data have emerged to support such strategy. Few clinical studies have been designed to evaluate the role of the link between TGFb1 overproduction and left ventricular abnormalities in HT patients. Accordingly, the aim of the present study was to determine the effect of 24 weeks losartan and ramipril administration on measurements of left ventricular geometry and function, and circulating TGFb1 together with serum collagen I and III in HT patients. For this reason, hypertensive subjects were allocated randomly to 24 weeks of treatment with ACEi and ARB alone or in combination.
Materials and methods

Patients
Subjects eligible for the study were screened for arterial hypertension at the antihypertensive centre of the Department of Internal Medicine, University of Palermo (Italy). Subjects with a casual systolic blood pressure (SBP) X140 mm Hg and o180 mm Hg and/or with casual diastolic blood pressure (DBP) X90 mm Hg and o110 mm Hg obtained with a standard sphygmomanometer after 5 min. of rest at three independent occasions, were invited to our day hospital for a detailed medical examination, including history taking, physical, routine laboratory and echocardiographyc examination. Exclusion criteria included the presence of any form of secondary hypertension; stage III essential hypertension, any irreversible end organ damage owing to arterial hypertension; metabolic bone disease, hyperthyroidism, cardiovascular disease, diabetes, dyslipidemia, hepatic disease, alcoholic liver disease, malignants. Accordingly, from a 328 consecutive hypertensive patients, we established three groups of patients single matched for age, gender, body mass index (BMI) , SBP and DBP. Fifty-seven patients fulfilled the selection criteria, and baseline characteristics of the study participants are given in Table 1 .
Study design and active treatment
Each patient gave a written consent after receiving a detailed description of study procedure. The study was approved by Ethics Committee of our Institution. Multiple comparisons power analysis was performed to determine the sample size. The primary end point was considered as the level of The total sample size resulted in 57 subjects (19 subjects for each of the three arms); it achieved 83% power using the Hsu (With Best) multiple comparison test at 0.05000 significance level. This study was a randomized, double-blind, three-arm double-dummy independent trial. It was planned and conducted according to the revised recommendations for improving the quality of report or randomized trial. 17 We studied three groups of subjects, each of them matched for age, BMI and BP values. Then groups were randomly allocated into one of the three therapy arms. The first arm was treated with losartan 50 mg/ day, the second arm was treated with ramipril 5 mg/ day and the third was treated with a combination of the two drugs (losartan 50 mg plus ramipril 5 mg; Figure 1 ). BP normalization (SBP o140 mm Hg and DBP o90 mm Hg) occurred in 54/57 HT. To achieve this goal, only few patients in each treatment group also received hydrochlorotiazide (12.5 mg once daily) (losartan group n ¼ 1 patient; ramipril group n ¼ 1 patient; combined group n ¼ 1 patient). The follow-up was 24 weeks. Each patient entered into the study was uniquely identified for study purposes by a four-digit patient number, and each group was labelled by a letter corresponding to drug regimen that was concealed until statistical analysis was completed.
The drug regimen was double-dummy, so each group received two tablets (one pharmacologically active plus placebo, except the group that received two pharmacologically active drugs). Both placebo and active drug tablets were indistinguishable but for a letter label. Severe adverse reactions were monitored to enable the study to be stopped early if they emerged. The patient code was revealed to the clinical researchers once recruitment, data collection, laboratory analyses and statistical analysis were completed. No patient dropped out from the study, so data of all patients were collected and analysed. An independent biostatistics expert analysed data and performed inferential analysis. All data analysis was performed according to a preestablished analysis plan and blinded regarding as therapy groups. The patients attended the clinic for a total of eight study visits: at 4 and 2 weeks before randomisation, at randomization (week 0) and at 1, 4, 6, 12, 18 and 24 weeks after randomization. At each visit, BP was measured in the morning after 5 min of rest, about 24 h after the previous drug administration. Sitting BP was measured three times with an interval of about 2 min, and the mean was calculated. Mean blood pressure (MBP) was calculated by the formula DBP plus 1/3 of pulse pressure. At 0 and 24 weeks after randomization, both biochemical and echocardiographic measurements, circulating TGFb1, procollagen type I (PIP) and III (PIIIP) were determined.
Measurements
Patients underwent a general analytical laboratory parameters profile including blood urea nitrogen, creatinine and clearance, glycaemia, electrolytes (serum sodium, potassium, chloride) by routine laboratory methods.
Biochemical determinations
Blood samples were drawn by venepuncture with care to minimise degranulation of the platelets and to avoid the release of TGF b1. Peripheral venous blood was obtained from each patient and the sera were isolated and stored at À701C. TGFb1 levels were determined by using a solid-phase-specific sandwich enzyme-linked immunosorbent assay (ELISA) technique (R&D Systems Inc., MN, USA) as described previously. 18 The inter assay and intraassay variations for determining TGFb1 were 8 and 6%, respectively. The sensitivity, hence minimum level of detection of TGFb1 by sandwich ELISA was 5 pg/ml. To determine PIP and PIIIP, blood samples were taken from each patient and stored at À401C until manipulation. PIP and PIIIP were determined by using a specific radioimmunoassay (Orion Diagnostic Finland), as described previously. 19, 20 The sensitivity of PIP was 1.20 pg/l. The inter-and intraassay variations for determining PIP were 7 and 3%, respectively. The sensitivity of PIIIP was 1 ng/ml, the intra-assay variations ranged from 1.7 to 4.3% and interassay variations from 3.2 to 5.3%. for men and X47 g/m 2.7 for women were considered to have LVH. The prevalence of HT patients with LVH into three treatment groups was not significantly different (Losartan group no. 10/19; Ramipril group no. 10/19; Combined treatment group no. 11/ 19). The relative wall thickness was also calculated by using the formula ((PWTd/LVIDd) Â 2). Ejection fraction from left ventricular end diastolic and endsystolic volumes was measured from the apical fourchamber view, using the ellipsoidal single-plane algorithm. Mean ejection fraction was automatically calculated by the echocardiographic processing system. In our laboratory, the ejection fraction calculated over five consecutive beats permitted optimal reproducibility and accuracy. 22 LV relaxation and filling were evaluated by pulsed-wave Doppler interrogation of the LV inflow tract from the apical four-chamber view, with the sample volume placed at the tips of the mitral valve. After a stable signal of the transmitral flow, velocity was obtained; the Doppler cursor was moved toward the LV outflow tract in the apical five-chamber view for recording both mitral and aortic signals, including the closing click of the aortic valve and the opening click of the mitral valve. Doppler signals were recorded at high speed (80-120 mm/s) with the subjects in held expiration. An average of five beats was used for analysis. Isovolumic relaxation time (IVRT) was calculated as the time from the closure click of the aortic valve to the opening click of the mitral valve. When either the closing or opening click was not identified, the time from the end of the aortic flow to the onset of mitral flow from the continuous wave interrogation of the LV inflowoutflow tract was used. Peak early transmitral flow velocity (E), peak late transmitral flow velocity (A) and the deceleration time of E velocity (DTE) were measured at the tips of mitral leaflets at the maximum amplitude of E velocity. DTE was measured as the time from peak E velocity to the time when E wave descent intercept the zero line.
Echocardiographic measurements
Statistical analysis
Data are expressed as mean value7s.d. Non-parametric tests were performed to test null hypothesis and two-sided value of Po0.05 indicated a statistical significant difference. The Wilcoxon-signed ranks test was performed to compare data at baseline and after treatment within groups. Groups' data both at baseline and after treatment changes were compared by the Kruskall-Wallis test used as a nonparametric alternative to the one-way ANOVA. Pairwise comparisons between groups were performed using the Conover-Inman method whether the Kruskall-Wallis had pointed out a significant among groups.
Results
No significant differences in baseline age, BMI, SBP, DBP, MBP, routine biochemical measurements, circulating TGFb1, PIP and PIIIP values and echocardiographic measurements were observed for the losartan, ramipril and combination group (Tables 1  and 2 ). Significant (Po0.05) decrease in SBP, DBP, MBP, total and LVM/h 2.7 , TGF b1, PIP and PIIIP values were observed in all the groups at the end of treatment compared to baseline values. A mild ; PWTd, posterior wall thickness; RWT; relative wall thickness. *Po 0.05 vs baseline. increase in TGFb1 was observed in one patient of the ramipril group at the end of treatment (11.2 vs 10 ng/ml). In all groups, no significant changes in biochemical measurements and in the remaining echocardiographic parameters were found at the end of treatment (Tables 1 and 2) . Figures 2 and 3 show the responses of TGFb1 and LVM/h 2.7 values of individuals to the three treatments. In the combination therapy group, a significant increase in the absolute reduction of TGFb1 (Po0.03 vs losartan; Po0.0001 vs ramipril) and of LVM/h 2.7 (Po0.05 vs losartan; Po0.001 vs ramipril) was found. The percent reduction in TGFb1 (Po0.03 vs losartan; Po0.0001 vs ramipril ) and in LVM/h 2.7 (Po0.05 vs losartan; Po0.03 vs ramipril) was also higher in the combination group. No significant changes in absolute and percent changes in SBP, DBP and MBP was detected among the three groups (Table 3) . Table 4 shows the effects of treatment on LVM, LVM/ h 2.7 and on percent reduction of LVM/h 2.7 in a subset of HTs with baseline LVH.
LVM and LVM/h 2.7 were significantly (Po0.05) reduced at the end of treatment in all groups. Percent reduction in LVM/h 2.7 was significantly higher in combined group than ramipril (Po0. and losartan (Po0.01). HT patients with normalised LVM/h 2.7 was likewise in all groups (losartan 6/10, ramipril 7/10 and combined 7/11). All treatment regimens were generally well-tolerated. Side effects were few and transient. Two patients complained of asthenia, two of cough and three of dizziness but treatments were not discontinued.
Discussion
In the present study, we hypothesised that inhibition of the RAS would be most beneficial in management of left ventricular geometry and function in hypertensive patients and might be achieved by a dual blockade with ACEi and ARB. To prove this hypothesis, we compared the effects of three treatments (monotherapy with ACEi and ARB and its combination) on BP, LVM and function, circulating TGFb1, type I and III collagen in hypertensive subjects. This was an independent single-centre trial, which compared with multicenter trials, may have some benefits, such as a simple design, strict implementation and constant analysis of clinical and laboratory data. This is the first study designed to analyse the effects of dual RAS blockade on LVM and function and circulating TGFb1 and type I and III collagen in HT patients. Our results indicate some interesting findings. First, a more marked reduction in left ventricular mass following the combination of ACEi and ARB than either drug alone has been found in hypertensive subjects. In fact, the reduction in LVM/h 2.7 after 6 months of combined therapy was significantly higher than LVM/h 2.7 reduction obtained with both single treatment, both in total HTsand in the subset with baseline LVH. This reduction was associated to unchanged EF and to a favourable trend in the measurements of diastolic function. It is important to emphasise that this effect was obtained with strict BP control in all the groups. This finding discounts the suggestion that the differences observed upon the reduction in LVM could be explained only by the systemic BP effect. Second, reduction in LVM/h 2.7 was associated with a strong decrease in circulating TGFb1, PIP and PIIlP values. Cardioprotection induced by combined therapy observed by us has been reported previously in experimental studies and in patients with hypertensive diastolic heart failure. 23 The exact mechanism of this finding is not entirely known but emerging data indicate a strong relationship among angiotensin II, TGFb1 overproduction, collagen turnover and left ventricular geometry and function. 10 Accordingly, our hypothesis about a better cardioprotective effect induced by combined RAS blockade might be related to the well-known effects of angiotensin II both on BP, systemic and cardiac haemodynamics 24, 25 and on inflammatory markers. 26 ACEi reduce angiotensin II but do not completely block the RAS, as angiotensin II may be produced via other non-ACE-mediated pathways. Blockade of AT1 by ARB may also reduce the unfavourable effects of angiotensin II. This might also induce an higher available angiotensin 24, 25 In particular, ARB also suppress some atherogenesis markers, such as cell-adhesion molecules, tumour necrosis factor-a and superoxide. 26 A combination of both agents may be more effective clinically than either one alone, and recent trials show promising results. 27, 28 In view of this, our data indicate that the additive cardioprotection obtained with a combined RAS blockade might be mediated through a concomitant reduction in circulating TGFb1 and collagen. This finding was supported by recent results indicating an important role of TGFb1 and collagen in the occurrence of myocardial fibrosis. In fact, recent experimental studies have shown that improvement of myocardial stiffness may be due to an inhibition of collagen synthesis rather than to an enhancement of collagen degradation. 29 Collagen synthesis is altered by load, activation of RAS, neurohumoral and growth factors. Chronic activation of the RAS increases extracellular matrix and fibrillar collagen, promoting myocardial stiffness and diastolic dysfunction. The use of treatment that blocks RAS might improve diastolic function through a normalization of fibrillar collagen. 30 The angiotensin II type receptor is the target of the RAS system and its activation promotes ventricular fibrosis and hypertrophy. 31 Experimental data have demonstrated that a combination of ACEi and ARB give additive favourable effects on ventricular structural abnormalities, diastolic dysfunction and collagen accumulation 32 that are independent by their antihypertensive effectiveness. These effects might be, in part, owing to the decrease of reactive oxygen species (ROS) generation. In fact, angiotensin II directly stimulates ROS production promoted by macrophage infiltration, 33 and the blockade of macrophage infiltration stop the production of TGFb1 34 and extracellular matrix. 35 Finally, combined therapy was characterized by a good safety profile and it was also supported by maintained renal function, left ventricular function and by inconsistent change in potassium at the end of the treatment. However, our study has some possible limitations. First, it did not have a placebo group; such group was not approved by the ethics committee because of the known cardioprotection of ACEi and ARB. This limitation is unlikely to affect our data because both monotherapies significantly reduced LVM. Second, we have not assessed the most appropriate dose of each drug in combination treatment. We do not know if a combination of reduced doses of both drugs could offer the same cardioprotection as the dose we used. In view of this, Peters et al. 36 reported that submaximal doses of ACEi and ARB, as we used, are able to induce in combination maximal inhibition of angiotensin II and provide maximal therapeutic efficacy. In addition, another study showed that addition of an ARB to an ACEi is more effective than doubling ACE-I dose. 37 Nevertheless dual RAS blockade is a relatively new concept and some questions remained unanswered. The duration of action of different ACEi and ARB might influence the effect of different combinations. Moreover RAS suppression and thus a higher dose or a shorter dose interval might be needed to obtain organ protection where lower doses are sufficient to treat hypertension. 38 Some clinical implications arise from the results of our study. First, combination treatment was well tolerated without evidence of hyperkalemia after 24 weeks. This provided further evidence to suggest that the suggestion of avoiding use of ACEi and ARB or both, to prevent renal impairment and hyperkalemia, is no longer justified. However, careful observation is still recommended. Second, the results of our study support the hypothesis that cardioprotective effects of the RAS inhibition were associated to suppression of TGFb1 and reduction in the type I and III collagen deposition. In conclusion, our data suggest that hypertensive patients with higher LVM and TGFb1 and collagen overproduction may be considered a particular subset of HT patients, who may particularly benefit from dual RAS blockade. This indication might also improve the therapeutic strategy for cardioprotection in hypertensive subjects.
